US Broker Ratings

Biogen Inc. (BIIB) Investor Outlook: Navigating a 29.98% Potential Upside Amidst Healthcare Innovations

Biogen Inc. (NASDAQ: BIIB), a stalwart in the healthcare sector, stands as a beacon for individual investors seeking exposure to the dynamic world of neurological and neurodegenerative disease therapies. With..

Fresenius Medical Care AG (FMS) Stock Analysis: Exploring 28% Potential Upside

Fresenius Medical Care AG (NYSE: FMS) stands as a significant player in the healthcare sector, specifically within the medical care facilities industry. Based in Bad Homburg, Germany, this $14.12 billion..

Becton, Dickinson and Company (BDX) Stock Analysis: Assessing a 9.33% Potential Upside

Becton, Dickinson and Company (NYSE: BDX), a venerable player in the healthcare sector, is garnering attention from investors due to its robust market position and the potential for a notable..

Novartis AG (NVS) Stock Analysis: What Investors Need to Know About Its 32.49% ROE and Strong Revenue Growth

Novartis AG (NYSE: NVS) is a juggernaut in the healthcare sector, standing as a key player in the general drug manufacturing industry. Headquartered in Basel, Switzerland, the company is renowned..

Takeda Pharmaceutical Company (TAK) Stock Analysis: Unveiling a 16.93% Potential Upside for Investors

Takeda Pharmaceutical Company Limited (NYSE: TAK), a prominent player in the healthcare sector, occupies a significant position in the drug manufacturing industry, specializing in both specialty and generic pharmaceuticals. With..

UnitedHealth Group (UNH) Stock Analysis: Exploring a 30% Potential Upside for Investors

UnitedHealth Group Incorporated (NYSE: UNH), a behemoth in the healthcare sector, commands a formidable presence with a market capitalization of $227.59 billion. As a key player in the healthcare plans..

Thermo Fisher Scientific Inc (TMO) Stock Analysis: A Closer Look at Its 19.77% Potential Upside and Strong Buy Ratings

Thermo Fisher Scientific Inc (NYSE: TMO) stands as a titan in the healthcare sector, operating within the diagnostics and research industry. With a robust market capitalization of $173.97 billion, the..

Agilent Technologies, Inc. (A) Stock Analysis: Unlocking a 19.48% Potential Upside in the Diagnostics & Research Sector

Agilent Technologies, Inc. (NYSE: A), a key player in the Healthcare sector, specializes in providing cutting-edge solutions in the diagnostics and research industry. With a market capitalization of $32.56 billion,..

GSK plc (GSK) Stock Analysis: Unlocking a 3.25% Potential Upside Amid Strong Dividend Yields

GSK plc (GSK), a prominent player in the Healthcare sector, stands out in the Drug Manufacturers – General industry with a substantial market cap of $76.23 billion. Based in the..

Merck & Company, Inc. (MRK) Stock Analysis: Strong Dividend Yield and Significant Upside Potential

Merck & Company, Inc. (NYSE: MRK) stands as a formidable player in the healthcare sector, specifically within the drug manufacturing industry. With a commanding market capitalization of $201.55 billion, Merck..

Medtronic plc (MDT) Stock Analysis: Exploring a 4.33% Potential Upside in the Robust Medical Devices Sector

Medtronic plc (NYSE: MDT), a titan in the healthcare sector, stands out as a dominant force in the medical devices industry with a market capitalization of $119 billion. Headquartered in..

Zoetis Inc. (ZTS) Stock Analysis: A 29% Upside Potential with Strong Buy Ratings

Investors seeking potential growth in the healthcare sector may find Zoetis Inc. (NYSE: ZTS) an intriguing opportunity. As a leading player in the specialized drug manufacturing industry, Zoetis stands out..

Alcon Inc. (ALC) Stock Analysis: Exploring a 22.65% Potential Upside for Investors

Alcon Inc. (NYSE: ALC), a global leader in eye care products, has captured the attention of investors with a promising potential upside of 22.65%. Headquartered in Geneva, Switzerland, Alcon operates..

Gilead Sciences, Inc. (GILD): Investor Outlook Amid Strong 2.65% Dividend Yield and Impressive Return on Equity

Gilead Sciences, Inc. (NASDAQ: GILD), a heavyweight in the healthcare sector, continues to attract investor attention with its robust portfolio of pharmaceuticals aimed at addressing critical unmet medical needs globally...

Pfizer, Inc. (PFE) Stock Analysis: Navigating a 17.4% Potential Upside with a Robust 7% Dividend Yield

Pfizer, Inc. (NYSE: PFE), a stalwart in the healthcare sector, has long been a cornerstone of drug manufacturing, recognized globally for its biopharmaceutical innovations. With a market capitalization of $139.75..

Cencora, Inc. (COR) Stock Analysis: Exploring a 16.46% Potential Upside in Healthcare Distribution

Cencora, Inc. (COR), a stalwart in the healthcare sector with a focus on medical distribution, is capturing investor interest with a promising potential upside of 16.46%. As the company continues..

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 17.78% Potential Upside

AstraZeneca PLC (AZN), a leading player in the healthcare sector, continues to capture investor interest with its robust pipeline and strategic collaborations. Headquartered in Cambridge, UK, AstraZeneca specializes in the..

Stryker Corporation (SYK) Stock Analysis: Healthcare Giant with 14.48% Upside Potential

Stryker Corporation (NYSE: SYK) stands as a formidable name in the healthcare sector, specializing in medical devices. With a market capitalization of $144.35 billion, Stryker’s influence and reach are substantial,..

Johnson & Johnson (JNJ) Stock Analysis: Evaluating the Healthcare Giant’s Growth Potential and Market Position

For investors seeking stability in the ever-fluctuating market, Johnson & Johnson (NYSE: JNJ) presents itself as a stalwart in the healthcare sector. With a market capitalization of $417.44 billion, the..

Eli Lilly and Company (LLY) Stock Analysis: A Look at 46.37% Potential Upside and Robust Revenue Growth

Eli Lilly and Company (NYSE: LLY), a prominent figure in the healthcare sector, is drawing significant attention from investors due to its impressive revenue growth and a potential upside of..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds